title: Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
abstract: Wild-type P16/CDKN2 (p16INK4A, MTS1) cDNA, directed by the cytomegalovirus (CMV) immediate early promoter, was transfected into RT4 and RT112 bladder-carcinoma cell lines bearing a mutated endogenous P16/CDKN2 gene and lacking endogenous P16/CDKN2 respectively. In both cases, only transfected clones with rearranged exogenous P16/CDKN2 cDNA could be grown and propagated in cell culture. This result is reminiscent of transfection of wild-type p53 into cells with a deleted or mutated endogenous gene and suggests that P16/CDKN2, over-expressed under control of the strong CMV promoter, induces growth arrest in RT4 and RT112 cells. Transfer of human chromosome 9 to RT4 cells produced RT4/H9 hybrid clones retaining the P16/CDKN2 gene, since in RT4/H9 cell clones P16/CDKN2-gene expression is modulated by the physiological control of chromosomal regulatory sequence. All the RT4/H9 clones lost the entire chromosome 9, except clone 4 and clone 5, which maintained a deleted and an intact chromosome 9 respectively. Loss of several loci in 9p21, including P16/CDKN2, in tumors induced in nude mice by clone 4 and clone 5 suggests that P16/CDKN2 or other genes in 9p21 suppress tumorigenicity in bladder-carcinoma cells. Tumors induced by clone 4 and clone 5 show loss of markers in 9q. The regions 9q22.3, 9q32-33 and 9q34.2, which were maintained in the 2 clones and lost in their derived tumors, may contain tumor-suppressor genes relevant in bladder carcinoma. The results of this study suggest that the P16/CDKN2 gene controls growth of bladder-carcinoma cells when it is over-expressed, and may be involved in the development of bladder carcinoma, but other genes in 9p21 and 9q may participate in bladder-cancer progression.
authors.affiliation: Institute of Microbiology, Center for Biotechnology, School of Medicine, University of Ferrara, Italy.
authors.forename: Q
authors.initials: Q
authors.lastname: Wu
authors.forename: L
authors.initials: L
authors.lastname: Possati
authors.forename: M
authors.initials: M
authors.lastname: Montesi
authors.forename: F
authors.initials: F
authors.lastname: Gualandi
authors.forename: P
authors.initials: P
authors.lastname: Rimessi
authors.forename: C
authors.initials: C
authors.lastname: Morelli
authors.forename: C
authors.initials: C
authors.lastname: Trabanelli
authors.forename: G
authors.initials: G
authors.lastname: Barbanti-Brodano
mesh_terms: D000818:Animals; D001483:Base Sequence; D016466:CHO Cells; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000473:pathology*; D002352:Carrier Proteins / Q000235:genetics* / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D002899:Chromosomes, Human, Pair 9; D006224:Cricetinae; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018076:DNA, Complementary / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008969:Molecular Sequence Data; D014162:Transfection; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology*
chemical_list: D002352:Carrier Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018076:DNA, Complementary